Beijing Genova Biotech Company, Ltd. Report issue

For profit Phase 2 Phase 3
Founded: Beijing China (2007)
Status: No NME R&D (2007)

Organization Overview

First Clinical Trial
2011
NCT01386242
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Genova Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

interferon alpha-2b (Intron-A) (4 trials)

Drugs in Phase 2 Trials (1)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2